Design of a phase 3, prospective, multicenter, open-label study of safety and hemostatic efficacy of rurioctocog alfa pegol in previously untreated patients <6 years of age with severe hemophilia A - Mullins, E; Kefurt, C; Engl, W; Tangada, S (Haemophilia, 2019)